Daniel Joseph Mccarthy Sells 65,892 Shares of Evolent Health (NYSE:EVH) Stock

Posted by Geri Gentry on Aug 28th, 2026

Evolent Health, Inc (NYSE:EVH – Get Free Report) President Daniel Joseph Mccarthy sold 65,892 shares of the stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $5.00, for a total value of $329,460.00. Following the transaction, the president owned 655,133 shares of the company’s stock, valued at $3,275,665. This represents a 9.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Evolent Health Price Performance

Shares of EVH stock traded up $0.02 on Friday, reaching $4.61. The company’s stock had a trading volume of 2,212,097 shares, compared to its average volume of 3,055,550. The stock’s fifty day simple moving average is $4.78 and its 200-day simple moving average is $3.83. Evolent Health, Inc has a 1 year low of $2.10 and a 1 year high of $10.08. The company has a market capitalization of $521.20 million, a price-to-earnings ratio of -1.01 and a beta of 0.79. The company has a current ratio of 1.24, a quick ratio of 1.24 and a debt-to-equity ratio of 2.52.

Evolent Health (NYSE:EVH – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The technology company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.03. Evolent Health had a negative net margin of 24.08% and a negative return on equity of 4.27%. The company had revenue of $484.50 million for the quarter, compared to the consensus estimate of $597.70 million. During the same quarter in the prior year, the firm earned ($0.10) earnings per share. Evolent Health’s revenue was up 46.9% on a year-over-year basis. Analysts forecast that Evolent Health, Inc will post -0.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Evolent Health

Several hedge funds have recently added to or reduced their stakes in the company. Corient Private Wealth LP raised its position in Evolent Health by 447.4% in the 2nd quarter. Corient Private Wealth LP now owns 81,594 shares of the technology company’s stock worth $442,000 after purchasing an additional 66,687 shares during the period. California State Teachers Retirement System boosted its position in shares of Evolent Health by 41.7% during the second quarter. California State Teachers Retirement System now owns 8,471 shares of the technology company’s stock valued at $46,000 after buying an additional 2,494 shares during the period. HB Wealth Management LLC boosted its holdings in Evolent Health by 6.8% during the 2nd quarter. HB Wealth Management LLC now owns 35,842 shares of the technology company’s stock valued at $194,000 after acquiring an additional 2,282 shares during the period. Headlands Technologies LLC grew its position in Evolent Health by 71.7% in the 2nd quarter. Headlands Technologies LLC now owns 29,292 shares of the technology company’s stock valued at $159,000 after acquiring an additional 12,232 shares during the last quarter. Finally, Public Employees Retirement System of Ohio bought a new position in Evolent Health in the 2nd quarter valued at $760,000.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Weiss Ratings downgraded shares of Evolent Health from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 18th. Needham & Company LLC boosted their price objective on Evolent Health from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Citigroup upgraded Evolent Health from a “neutral” rating to a “buy” rating and decreased their price objective for the company from $6.75 to $6.00 in a research report on Monday, August 10th. Canaccord Genuity Group lowered their price objective on Evolent Health from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Monday, August 10th. Finally, JPMorgan Chase & Co. lifted their target price on Evolent Health from $5.00 to $6.00 and gave the stock an “overweight” rating in a report on Tuesday, August 18th. Eleven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.96.

Check Out Our Latest Analysis on EVH

About Evolent Health

(Get Free Report)

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.